ArticlePloS one2026

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer.

Ou Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.